Macomics launches fundraising for Prof. Jeffrey Pollard Memorial Fund

Macomics Ltd, a leader in macrophage drug discovery, is delighted to announce that it has launched the Macomics Hyper-Triathlon Challenge, in honour of its co-founder Prof. Jeffrey Pollard, who passed away earlier this year, to raise funds for the newly established Jeff Pollard’s memorial fund.

The new charitable fund, managed by the University of Edinburgh where Prof. Pollard was Director of the MRC Centre for Reproductive Health, will be used to organise scientific meetings focused on macrophage biology, and to fund travel and enrichment grants aimed at early career researchers.  

Macomics was founded on the breakthrough research of Prof. Pollard and Dr. Luca Cassetta, from the University of Edinburgh, to develop cancer therapeutics against novel targets on macrophages.

Dr Luca Cassetta, VP immunology and co-founder of Macomics said, “To celebrate Jeff’s achievements as a world leader in macrophage biology and a mentor, and to commemorate his impact on our company, Macomics team decided to help raise money for the newly established Jeff Pollard’s memorial fund.”

Macomics has two laboratories, one located in Roslin Innovation Centre, near Edinburgh and the other on Cambridge Science Park.

“Although our two sites are separated by 460km in a straight line, we are one team working for the benefits of cancer patients. To prove that this distance is not a barrier, the Macomics Hyper-Triathlon Challenge will consist of 46km of swimming, 460km of running/walking, and 4600km of cycling over the slightly more than 4 months period” explained Cassetta.

As well as linking Macomics’ staff on two sites, the challenge reflects the company’s goal to connect macrophage biology from cancer research to cancer treatments. with cancer: the challenge started on September 24th, which was World Cancer Research Day and finishes on February 4th, which is World Cancer Day.

 

More news and updates 

SiSaf’s bio-courier technology enables clinical trial success for topical treatment of mild to moderate Alopecia areata

SiSaf Ltd announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomised, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate (patchy) alopecia areata.

Manchester Met opens applications for September cohort of degree apprenticeships in science and sustainability

Employers looking for new talent or to upskill their current workforce can benefit from degree apprenticeships, starting Autumn 2024.

Discovery Park partners with Canterbury Christ Church University to open CoLab

Discovery Park, Kent’s thriving life science community, has opened the doors to CoLab, a new shared lab facility. In partnership with Canterbury Christ Church University, CoLab has been specially designed for early-stage life science businesses, providing flexible bench space in a collaborative coworking environment.

New blood test could prevent sudden child deaths caused by hereditary heart condition

A new blood test that could identify children with a potentially fatal heart condition has been developed by researchers at UCL (University College London) and Great Ormond Street Hospital (GOSH), thanks to investment from the charity Action Medical Research and self-funded not-for-profit, LifeArc.

Macomics announces appointment of Simon Dew as new Chief Business Officer

Macomics Ltd, a leader in macrophage drug discovery has announced the appointment of Simon Dew in the newly created position of Chief Business Officer (CBO). He will be instrumental in advancing Macomics’ mission to develop first-in-class medicines targeting macrophage-driven diseases of high unmet medical need, in oncology and chronic inflammatory diseases.

Bruntwood SciTech launches all new life science accelerator at Alderley Park

We’re delighted to announce the launch of the life science accelerator at Alderley Park, powered by Bruntwood SciTech and funded by the UK Government through the UK Shared Prosperity Fund. This initiative is designed to support early-stage life science companies across the UK, driving innovation and economic growth in the North West.

Biomanufacturing policy summit report 2024: policy pathways for biomanufacturing in Europe

This report summarises the summit’s main discussion points and takeaways and uses them as a foundation to build a strengths, weaknesses, opportunities and threats (SWOT) analysis for biomanufacturing in Europe.

Brandon Capital announces sixth fund with $270 million initial close to drive life science innovation

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at $270 million.

RSSL opens doors to innovation for the first time with exclusive behind-the-scenes event

RSSL, for the first time, will be opening their doors to not just clients. Providing a unique opportunity to the industry to delve into the science that drives innovation and see first hand what happens behind the scenes at RSSL.

Medannex unveils first-in-human study of novel cancer therapy at ASCO 2024

Medannex Ltd (Edinburgh) today revealed details of the attainment study at the American Society of Clinical Oncology (ASCO) annual meeting. The phase 1b oncology study is the first clinical evaluation of a therapy targeting annexin-A1, a new and unique cancer target.

 

More within